S&P Futures
6,008.00 +4.25 (+0.07%) Dow Futures
43,899.00 -11.00 (-0.03%) Nasdaq Futures
21,232.25 +7.50 (+0.04%) Russell 2000 Futures
2,399.40 +3.70 (+0.15%) Crude Oil
71.26 -1.10 (-1.52%) Gold
2,695.60 -10.20 (-0.38%)
BioSenic S.A. (BIOS.BR)
| Previous Close | 0.0084 |
| Open | 0.0084 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0084 - 0.0086 |
| 52 Week Range | 0.0038 - 0.0978 |
| Volume | |
| Avg. Volume | 2,826,558 |
| Market Cap | 2.284M |
| Beta (5Y Monthly) | -2.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Oct 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.10 |
GlobeNewswireBioSenic provides third quarter 2024 Business Update
BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024. Key highlights In July 2024
- GlobeNewswire
BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparen
